European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact
Guidelines

Testicular Cancer

Want to read the guideline in your own time? Download the PDF

Download full guideline

Looking for a quick overview? Check the pocket guidelines.

Download pocket guidelines
Full text guidelineSummary of ChangesPublications & AppendicesPanelRelated content
No results found
  1. Introduction
  2. Methods
  3. Epidemiology Aetiology Pathology
  4. Staging & Prognosis
  5. Diagnostic Evaluation
  6. Disease Management
  7. Follow Up After Curative Therapy
  8. Rare Adult Para And Testicular Tumours
  9. References
  10. Conflict Of Interest
  11. Citation Information
  12. Copyright And Terms Of Use
7. Follow Up After Curative Therapy
  • 1. Introduction
  • 2. Methods
  • 3. Epidemiology Aetiology Pathology
  • 4. Staging Prognosis
  • 5. Diagnostic Evaluation
  • 6. Disease Management
  • 7. Follow Up After Curative Therapy
  • 8. Rare Adult Para And Testicular Tumours
  • 9. References
  • 10. Conflict Of Interest
  • 11. Citation Information
  • 12. Copyright And Terms Of Use
  • No elements found. Consider changing the search query.
  • List is empty.

7. FOLLOW UP AFTER CURATIVE THERAPY

7.1. Minimal recommendations for follow-up

Based on different risks of relapse depending on diagnosis and initial treatment, three major follow-up groups can be defined:

  1. patients with seminoma stage I;
  2. patients with non-seminoma stage I on AS;
  3. all patients having received either adjuvant treatment or curative chemotherapy for good- and intermediate-prognosis metastatic disease (according to the IGCCCG) achieving a complete remission with, or without, surgery (for seminoma this includes residual lesions < 3 cm, or residual lesions > 3 cm that are FDG-PET-negative).

It is important to note that patients not achieving a complete remission or presenting with poor-prognosis disease should be followed up individually by specialised centres. Tables 8-10 show the minimal recommendations for follow-up of the three different groups based on recommendations developed at a European Society for Medical Oncology (ESMO) consensus conference [268].

Both MRI and CT can be used to evaluate the retroperitoneum, pelvis and inguinal regions for sites of metastatic disease from GCT [269,270]. Magnetic resonance imaging benefits from an absence of ionising radiation but is more time consuming and less readily available than CT [271]. Given the frequency of follow-up, over a number of years some studies have estimated a risk of up to 1 in 300 of second malignancy related to CT imaging follow-up alone [272], although more recent dose saving protocols and limitations on field of view will have mitigated this somewhat. Nevertheless, this risk could be excluded by the use of MRI for follow-up.

Both MRI and CT rely predominantly on size cut-offs for evaluation given the excellent spatial resolution of both modalities, with morphological assessment for features such as necrosis and irregular shape an adjunct. Sensitivity and specificity vary according to the size cut-off used [269]. However, studies have shown comparable excellent results between MRI and CT with up to 98% sensitivity on MRI for the detection of retroperitoneal nodal metastases in GCT [273]. It has, however, been demonstrated that reader experience is important when interpreting images [274]. In the setting of GCT, one study demonstrated decreased sensitivity for detection of retroperitoneal nodal disease on MRI when reported by a trainee radiologist with sensitivity of detection of 80% [272]. However, experienced radiologists in the same study achieved sensitivity for detection of nodal disease of 97% with good interobserver agreement. It was therefore suggested that if MRI is to be used instead of CT for follow-up this be done in centres/units with oncological radiologists who routinely report MRI and CT in patients with GCT, rather than general radiologists who may only occasionally see such imaging. Consequently, MRI of the abdomen can be used as an alternative to CECT in experienced centres [275].

The diagnostic accuracy of FDG-PET-CT is best described and therefore recommended in seminoma patients with post-chemotherapy residual masses > 3 cm in largest diameter as outlined in section 6.3.2.1. This should be performed at least two months after completion of chemotherapy as earlier scans may be misleading due to inflammation. The changes are related to tumour necrosis. The use of FDG-PET-CT is not currently recommended during surveillance. Retrospective analyses have indicated a high diagnostic accuracy for staging and follow-up in patients with CS 1 during surveillance or for determining the stage in more advanced disease [276]. However, to minimise radiation exposure and considering the supporting data for the use of MRI [270], the panel currently do not recommend the use of FDG-PET-CT during surveillance.

Serum tumour markers are the least invasive and most accessible follow-up investigations. The established serum tumour markers, such as AFP, β-hCG, and LDH, may yield false positive results, so their levels should be correlated with imaging findings or repeated in serial measurements [277]. Serum tumour markers can detect microscopic disease that is not yet visible on cross-sectional imaging in a small proportion of patients, and therefore, they should be measured at the recommended prescribed intervals [278].

MiR-371a-3p has a high diagnostic accuracy for detecting all histologies of GCT except teratoma and has potential to detect disease recurrence earlier than AFP, β-hCG, LDH, or cross-sectional imaging [279]. However, before this promising test can be recommended in routine practice, a validated assay and cut-off definitions in prospective cohorts are required to mitigate the risk of false positive findings, unnecessary restaging, anxiety, or over-treatment.

Regarding the use of US examination of the contralateral testis, the majority of the consensus meeting participants did not support repeat US investigation, either with negative biopsy or if no contralateral biopsy has been performed [268].

A very late relapse (VLR) after five years is a rare event occurring in approximately 0.5% of patients based on a population-based analysis [257]. The aim of follow-up beyond five years therefore shifts to detection of late side effects of treatment and imaging tests are not routinely recommended.

Most patients with VLR are diagnosed due to symptoms, although in up to 50% elevated tumour markers are present in NSGCTs [257,280]. Patient education regarding relapse symptoms and clinician awareness are important elements of survivorship management. Early use of imaging and tumour markers with suspicion of relapse is encouraged.

Table 8: Recommended minimal follow-up for seminoma clinical stage I on active surveillance or after adjuvant treatment (carboplatin or radiotherapy)

ModalityYear 1Year 2Year 3Years 4 & 5After 5 years

Tumour markers

± doctor visit

2 times2 times2 timesOnceFurther management according to survivorship care plan
Chest X-ray----
Abdominopelvic magnetic resonance imaging (MRI)/computed tomography (CT)2 times2 timesOnce at 36 monthsOnce at 60 months

Table 9: Recommended minimal follow-up for non-seminoma clinical stage I on active surveillance

ModalityYear 1Year 2Year 3Year 4 & 5After 5 years

Tumour markers

± doctor visit

4 times*4 times2 times1-2 timesFurther management according to survivorship care plan
Chest X-ray2 times2 timesOnce, in case of LVI+At 60 months if LVI+
Abdominopelvic magnetic resonance imaging (MRI)/computed tomography (CT)2 timesAt 24 months**Once at 36 months***Once at 60 months***

* In case of high-risk (LVI+) a minority of the consensus group members recommended six times.
** In case of high-risk (LVI+) a majority of the consensus group members recommended an additional CT at eighteen months.
*** Recommended by 50% of the consensus group members.
LVI+ = Lymphovascular invasion present.

Table 10: Recommended minimal follow-up after adjuvant treatment or complete remission for advanced disease (excluded: poor-prognosis and no remission)

ModalityYear 1Year 2Year 3Year 4 & 5After 5 years
Tumour markers ± doctor visit4 times4 times2 times2 timesFurther management according to survivorship care plan**
Chest X-ray1-2 timesOnceOnceOnce
Abdominopelvic magnetic resonance imaging (MRI)/computed tomography (CT)1-2 timesAt 24 monthsOnce at 36 monthsOnce at 60 months
Thorax CT1-2 times*At 24 months*Once at 60 months*Once at 60 months*

* In conjunction with abdominopelvic MRI/CT in case of pulmonary metastases at diagnosis.
** In case of teratoma in resected residual disease: the patient should remain with the uro-oncologist.

7.2. Quality of life and long-term toxicities after cure of testicular cancer

The vast majority of patients will be cured with five-year relative survival rates of approximately 95% in Western Europe. Testicular cancer patients are usually between 18-40 years of age at diagnosis and life expectancy after cure extends over several decades [281]. Patients should be informed before treatment of common long-term toxicities, which are avoided or minimised by adherence to international guidelines.

During follow-up, patients should be screened and treated for known risk factors such as hypertension, hyperlipidaemia, and testosterone deficiency. Adverse health outcomes (AHOs) are more commonly found in TC patients who received chemotherapy than those cured by surgery alone. Further, modifiable risk factors do contribute to AHOs like hypertension and noise exposure to hearing impairment or smoking to Raynaud phenomenon [282]. Therefore, a healthy lifestyle should be promoted during the follow-up consultations. Adverse health outcomes are associated with unemployment, which is found clearly increased in TC survivors (TCSs) as compared to a male normative population [283]. When follow-up by the TC clinician is terminated, a written cancer survivorship plan addressing late toxic effects, lifestyle recommendations, recurrence risk, and cancer-specific follow-up may be helpful [200,284].

*For more information regarding long term toxicities and QoL issues, please see appendix 5, available online https://uroweb.org/guidelines/testicular-cancer/publications-appendices

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer